CASE STUDY: PROVIDING PRE-LAUNCH ACCESS

A top 10 pharmaceutical company had an innovative new immune-oncology medicine that represented a new treatment option for patients with advanced melanoma and other solid tumors.

There was extremely high awareness and demand, and the client wanted to respond positively to all requests for access whilst not negatively impacting their longer-term commercialization goals for the medicine.

Read the case study to discover how Clinigen enabled the company to provide pre-launch access to more than 5,000 patients with unmet medical needs and ensure fair and equitable access across all countries and populations.